Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

The global COVID-19 Therapeutics market size was valued at US$ 10.2 Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record a promising CAGR of 10.7% from 2021 to 2030.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

COVID-19 is a contagious disease triggered by the most recently discovered coronavirus, which has affected millions of individuals worldwide. The coronavirus can be treated with various drugs, including corticosteroids, antivirals, monoclonal antibodies, and kinase inhibitors. In August 2021, The World Health Organization (WHO) released a report that represents Artesunate, imatinib, and infliximab are three new potential medications being investigated in the latest phase of the global Solidarity clinical trials to find effective COVID-19 therapies. Additional medicines approved for emergency use include Eli Lilly and Company’s monoclonal antibodies bamlanivimab with etesevimab; Regeneron’s casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechology’s Xevudy (sotrovimab); Roche’s Actemra; Celltrion’s Regkirona; and convalescent plasma. The growth of the COVID-19 Therapeutics Market is primarily attributed the increased prevalence of COVID-19 across the globe. In the first week of January 2022, Covid-19 cases have now been recorded in over 300 million people worldwide. The United States had over 50 million confirmed cases and over 800,000 deaths, making it the Country with the highest death toll. Pharmaceutical companies are investing heavily in product research due to the rising pandemic effect, and they are focusing on the production of enhanced therapeutics that can cure the covid-19. The market is further supported by rising awareness about coronavirus and collective efforts by the pharmaceutical companies and government in the development of covid-19 therapeutic drugs.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

The prominent players in the COVID-19 Therapeutics industry include Atea Pharmaceuticals, Inc., Fulcrum Therapeutics, CytoDyn, Eli Lilly and Company, Celltrion, Shanghai Junshi Biosciences Co., Ltd., NRX Pharmaceuticals, Veru Inc., Catalent, Inc., Humanigen, Inc., Molecular Partners AG, Cipla Limited, Merck, Regeneron Pharmaceuticals, Inc., Novartis International AG, Vir Biotechnology, Brii Biosciences Limited, Revive Therapeutics Ltd., GlaxoSmithKline plc, APEIRON Biologics AG, Janssen Pharmaceuticals, Bristol Myers Squibb, Trevena Inc, Constant Therapeutics LLC, Ono Pharmaceutical Co., Ltd., Amarin Corporation plc, NeuroBo Pharmaceuticals, Inc., FUJIFILM Toyama Chemical Co., Ltd., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, Sorrento Therapeutics, PhaseBio, BioAegis Therapeutics, Pfizer, Takeda, Roivant Sciences, Celltex Therapeutics, Blade Therapeutics, A.I. Therapeutics, Inc., Marinomed Biotech AG, Synairgen, Romark Laboratories, SAb Biotherapeutics, Kiniksa Pharmaceuticals, UNION therapeutics A/S, etc.

COVID-19 Therapeutics Market Regional Analysis

In 2021, North America is expected to have the largest share of R&D in the global covid-19 therapeutics market, owing to increased government spending on drug development, growing government initiatives for covid-19 vaccine R&D, an increasing number of market players, and the implementation of favorable government initiatives in the U.S. and Canada. However, due to increased government initiatives to increase medication production and the number of research and development activities, the Asia Pacific area is predicted to grow rapidly in the target market. In June 2021, India’s pharma regulator approved the emergency use of Eli Lilly and Company India’s antibody medication combination, which is used to treat mild to moderate COVID-19 patients. The monoclonal antibody medications bamlanivimab 700 mg, and etesevimab 1400 mg have been approved by the company. Both of these medicines are utilized to treat COVID-19 patients who have mild to moderate symptoms.

The Global COVID-19 therapeutics Market Segments : Antiviral , Monoclonal Antibodies, Glucocorticoid, Anticoagulant, Nitric oxide and Other Drug Class.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

Source : https://www.bloomberg.com/press-releases/2022-01-18/global-covid-19-therapeutics-market-worth-14-6-billion-by-2022-exclusive-report-by-insightace-analytic and https://www.insightaceanalytic.com/report/global-covid-19-therapeutics-market/1184